Infliximab can reduce mortality from 35 to 14% in critically ill patients with COVID-19: perhaps some potential confounders to consider

Crit Care. 2020 Oct 9;24(1):603. doi: 10.1186/s13054-020-03294-7.

Authors

Patrick M Honore¹, Leonel Barreto Gutierrez², Luc Kugener², Sebastien Redant², Rachid Attou², Andrea Gallerani², David De Bels²

Affiliations

¹ ICU Department, Centre Hospitalier Universitaire Brugmann-Brugmann University Hospital, Place Van Gehuchtenplein, 4, 1020, Brussels, Belgium. Patrick.Honore@CHU-Brugmann.be.
² ICU Department, Centre Hospitalier Universitaire Brugmann-Brugmann University Hospital, Place Van Gehuchtenplein, 4, 1020, Brussels, Belgium.

No abstract available

Publication types

Letter
Comment

MeSH terms

Betacoronavirus
COVID-19
Calcinosis
Coronavirus Infections*
Critical Illness* / epidemiology
Cytokines
Heart Valve Diseases
Humans
Hypotrichosis
Infliximab
Pandemics*
Pneumonia, Viral*
SARS-CoV-2
Skin Diseases, Genetic

Substances

Cytokines
Infliximab

Supplementary concepts

Storm Syndrome